GSK reached its highest level since 2021 on Wednesday after the pharma group announced upbeat 2025 results and an encouraging pipeline of new treatments.
GSK reported total sales of £32.7 billion for 2025, up 7% at constant exchange rates, driven by robust growth across its Specialty Medicines portfolio.
The pharmaceutical giant’s Specialty Medicines division posted sales of £13.5 billion, rising 17%. Oncology led the way with 43% growth, whilst HIV sales climbed 11% to £7.7 billion. The company’s Respiratory, Immunology & Inflammation franchise grew 18% to £3.8 billion.
Vaccine sales reached £9.2 billion, up 2%. Shingrix, GSK’s shingles vaccine, advanced 8% to £3.6 billion. Meningitis vaccines rose 12% to £1.6 billion.
Investors were clearly pleased to see operating profit double amid rising sales as shares headed towards the 2,000p level.
“GSK enters 2026 with a renewed sense of purpose and, for the first time in years, looks ready to step out from the long shadow of AstraZeneca. Under new CEO Luke Miels, momentum has accelerated as pipeline execution sharpens and operational delivery improves,” explained Mark Crouch, market analyst for eToro.
“A Q4 sales and profit beat was driven by broad-based double-digit growth across higher-value specialty franchises. Oncology continues to stand out, while Respiratory, Immunology and HIV all delivered excellent gains, reinforcing confidence that GSK’s growth is by no means reliant on a single pillar.
“Management now guides to 3–5% revenue growth in 2026, following a strong 7% advance in 2025. While that implies moderation, it also signals a more disciplined and sustainable trajectory. Shares have broken above levels not seen in over two decades, pointing to a genuine shift in investor sentiment after years of mediocrity.”
GSK shares were 2.3% higher at the time of writing.